VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | Azacitidine and decitabine in treatment naive AML patients

Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, discusses the comparative results of azacitidine and decitabine from a large prospective Phase III study in treatment-naive acute myeloid leukemia (AML) not eligible for intensive chemotherapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter